255 related articles for article (PubMed ID: 32693294)
1. Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.
Nebigil CG; Moog C; Vagner S; Benkirane-Jessel N; Smith DR; Désaubry L
Eur J Med Chem; 2020 Oct; 203():112653. PubMed ID: 32693294
[TBL] [Abstract][Full Text] [Related]
2. Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A.
Basmadjian C; Thuaud F; Ribeiro N; Désaubry L
Future Med Chem; 2013 Dec; 5(18):2185-97. PubMed ID: 24261894
[TBL] [Abstract][Full Text] [Related]
3. Comparative phytochemistry of flavaglines (= rocaglamides), a group of highly bioactive flavolignans from
Greger H
Phytochem Rev; 2022; 21(3):725-764. PubMed ID: 34104125
[TBL] [Abstract][Full Text] [Related]
4. Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species.
Agarwal G; Chang LS; Soejarto DD; Kinghorn AD
Planta Med; 2021 Oct; 87(12-13):937-948. PubMed ID: 33784769
[TBL] [Abstract][Full Text] [Related]
5. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
6. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
Müller C; Obermann W; Karl N; Wendel HG; Taroncher-Oldenburg G; Pleschka S; Hartmann RK; Grünweller A; Ziebuhr J
Antiviral Res; 2021 Feb; 186():105012. PubMed ID: 33422611
[TBL] [Abstract][Full Text] [Related]
7. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
Xu J; Shi PY; Li H; Zhou J
ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
[TBL] [Abstract][Full Text] [Related]
8. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.
Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S
Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018
[TBL] [Abstract][Full Text] [Related]
9. Natural product-derived phytochemicals as potential agents against coronaviruses: A review.
Mani JS; Johnson JB; Steel JC; Broszczak DA; Neilsen PM; Walsh KB; Naiker M
Virus Res; 2020 Jul; 284():197989. PubMed ID: 32360300
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
11. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.
Panera N; Tozzi AE; Alisi A
Drugs; 2020 Jul; 80(10):941-946. PubMed ID: 32451923
[TBL] [Abstract][Full Text] [Related]
12. [Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].
Tian L; Liu W; Sun L
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):605-611. PubMed ID: 32347055
[TBL] [Abstract][Full Text] [Related]
13. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
14. A global treatments for coronaviruses including COVID-19.
Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
[TBL] [Abstract][Full Text] [Related]
15. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
16. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
17. The combined therapy of a traditional Chinese medicine formula and Western medicine for a critically ill case infected with COVID-19.
Zhang K; Tian M; Zeng Y; Wang L; Luo S; Xia W; Zhang X; Zha Y
Complement Ther Med; 2020 Aug; 52():102473. PubMed ID: 32951723
[TBL] [Abstract][Full Text] [Related]
18. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
Krishna G; Pillai VS; Veettil MV
Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
[TBL] [Abstract][Full Text] [Related]
19. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
20. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
[Next] [New Search]
